Theravance halves headcount, ends all R&D work after phase 3 rare disease fail
Theravance halves headcount, ends all R&D work after phase 3 rare disease fail
本文は利用できません。元の情報源をご確認ください。
Theravance halves headcount, ends all R&D work after phase 3 rare disease fail